Cognitive impairment is a significant characteristic of schizophrenia, contributing to poor functional outcomes. At the neurochemical level, N-methyl-d-aspartate receptor (NMDAR) antagonists can mimic schizophrenia-related neurocognitive dysfunction, prompting the development of treatments targeting NMDAR and its interactome. Researchers noted that, although no treatments have been approved for schizophrenia-related cognitive impairment, several promising candidates are undergoing early-phase testing.
Reference: Javitt DC. Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment. Annu Rev Pharmacol Toxicol. 2023 Jan 20;63:119-141. doi: 10.1146/annurev-pharmtox-051921-093250. Epub 2022 Sep 23. PMID: 36151052.
Link: https://schizophrenia.pocn.com/treatment/targeting-cognitive-impairment-in-schizophrenia-treatment/
